STREAM C: Celebrating 60 years of Yellow Card scheme reporting: Paving the way for future patient safety

STREAM C: Celebrating 60 years of Yellow Card scheme reporting: Paving the way for future patient safety

Charter 3
Medicines safety – Minimising medication error and waste

Information

Join us for an insightful presentation celebrating the 60th anniversary of the Yellow Card scheme, a cornerstone of patient safety and vigilance for medical products in the UK. 

  • This session will share significant milestones achieved over the past six decades and explore how the Medicines and Healthcare products Regulatory Agency (MHRA) is leveraging cutting-edge technologies, including artificial intelligence (AI), to enhance proactive patient safety measures for the future.
  • Hear from Alison Cave, Chief Safety Officer and other key patient and healthcare voices, on how we can ensure robust vigilance and optimal patient outcomes by asking healthcare professionals, patients, and stakeholders to actively participate in shaping the next era of the Yellow Card scheme
  • A compelling call to action for healthcare professionals, patients, and stakeholders to actively participate in shaping the next era of the Yellow Card scheme
  • Key themes will include the transformative role of AI in detecting, managing adverse drug reactions and a compelling call to action for healthcare professionals, patients, and stakeholders to actively participate in shaping the next era of the Yellow Card scheme. 
Agenda
HSJ Patient Safety Congress
Medicines and Healthcare products Regulatory Agency (MHRA)Stand 28Who are we? The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. We put patients first in everything we do, right across the lifecycle of the products we regulate. We rigorously use science and data to inform our decisions, enable medical innovation and to make sure that medicines and healthcare products available in the UK are safe and effective. Our responsibilities are to: ensure medicines, medical devices and blood components for transfusion meet applicable standards of safety, quality and efficacy (effectiveness) secure safe supply chain for medicines, medical devices and blood components promote international standardisation and harmonisation to assure the effectiveness and safety of biological medicines educate the public and healthcare professionals about the risks and benefits of medicines, medical devices and blood components, leading to safer and more effective use enable innovation and research and development that is beneficial to public health collaborate with partners in the UK and internationally to support our mission to enable the earliest access to safe medicines and medical devices and to protect public health What is the Yellow Card scheme? The MHRA runs the Yellow Card scheme, which collects and monitors information on suspected safety concerns involving healthcare products, like a side effect with a medicine or an adverse medical device incident. The scheme relies on voluntary reporting of problems to a healthcare product by the public (including patients, parents and carer givers) as well as from healthcare professionals. The scheme also collects suspected safety concerns involving defective (not of an acceptable quality), falsified or fake healthcare products. What is Yellow Card Biobank? The Yellow Card Biobank, is a collaboration between the MHRA and Genomics England, investigating pharmacogenomic links to adverse drug reactions. We are looking for patients that have experienced severe bleeds from direct oral anticoagulants and severe skin reactions from allopurinol to join the study or healthcare professionals that see these patients. Please come to the Yellow Card stand to ask questions you might have, or contact: yellowcardbiobank@mhra.gov.uk Please look at our short animation on what the Yellow Card Biobank is and what steps are involved for a patient joining.

Documents & Links

MHRA Presentation
Key Takeaways

Registered attendees

Dr Yogini Jani
Dr Yogini Jani
Director; Honorary Associate ProfessorUCLH-UCL Centre for Medicines Optimisation Research & Education (CMORE); UCL School of Pharmacy
Jyotika Singh
Jyotika Singh
Senior Principal ConsultantHSJ